PERUBAHAN KADAR sST2 SETELAH PEMBERIAN TERAPI KOMBINASI ACE- INHIBITORS DAN β-BLOCKERS PADA PASIEN INFARK MIOKARD AKUT (Penelitian Dilaksanakan di ICCU dan IRNA SMF Kardiologi dan Kedokteran Vaskular RSUD Dr. Soetomo Surabaya)
| Main Author: | Khoirunnisa, 051515153016 |
|---|---|
| Format: | Thesis NonPeerReviewed Book |
| Bahasa: | ind |
| Terbitan: |
, 2017
|
| Subjects: | |
| Online Access: |
http://repository.unair.ac.id/70563/1/TFK.%2015-18%20Kho%20p%20Abstrak.pdf http://repository.unair.ac.id/70563/2/TFK.%2015-18%20Kho%20p.pdf http://repository.unair.ac.id/70563/ http://lib.unair.ac.id |
Daftar Isi:
- BACKGROUND: Suppression of Tumorigenicity (ST2) is a receptor for interleukin-33 (IL-33), excreted by living cell as a response to cellular damage due to mechanical stretch cardiomyocytes. Identification of this cardiomarker can be a sign of worsening clinical condition or as a prognostic and therapy evaluation factor in acute myocardial infarction (AMI) patients. Basic management in AMI is with balancing oxygen supply and demand. Combination therapy of ACE-Inhibitors and β-blockers work on modulating pathophysiology-related neurohormonal system and sympathic activity, as a consequence, the combination therapy will be able to lowered sST2 concentration in AMI. In Dr. Soetomo Teaching Hospital, combination therapy is frequently prescribed for inpatients. OBJECTIVES: to analyze the change of sST2 concentration after ACE-Inhibitors and β- blockers combination therapy in acute myocardial infarction inpatients in Dr. Soetomo Teaching Hospital. METHODS: this was a prospective observational study. Conducted in ICCU and Cardiovascular ward of Dr. Soetomo Teaching Hospital from July-December 2017. Blood samples from patients who met inclusion criteria were extracted before combination therapy as baseline and on the fourth day as post. sST2 were measured using Quantikine® ELISA: Human ST2/IL-33 R Immunoassay. This kit was using quantitative sandwich enzyme immunoassay techniqu. RESULTS: Total of 12 patients were included (11 male). After combination therapy, means of sST2 pre and sST2 post were significantly decreased, 492.7 ± 472.2 ng/mL to 46.9 ± 45.8 ng/mL (p<0.05). 15.5% decrease from baseline concentration showed clinically significant improvement in physiology condition. sST2 concentration lower than cut off 35 ng/mL showed better prognosis, three times lower in 30-days mortality. From 12 patients, sST2 concentration of 11 patients declined >15.5% (69.5%-98%) and there was 9 patients achieved concentration lower than cut off point. CONCLUSION: There was a significant decrease in sST2 cencentration after ACEInhibitors and β-blockers combination therapy in AMI patients.